This trial is testing two different chemotherapy drugs (capecitabine and temozolomide) against a radioactive drug (lutetium Lu 177 dotatate) to see which is more effective at killing pancreatic neuroendocrine tumor cells in patients with advanced disease.
1 Primary · 10 Secondary · Reporting Duration: Up to 8 years from randomization
198 Total Participants · 2 Treatment Groups
Primary Treatment: Capecitabine · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: